Richard Gabriel, B.S., M.B.A., Life Sciences Entrepreneur, Joins CSG Advisory Board; Deirdre Y. Gillespie, M.D., Steps Down After 15 Years
- Adds deep experience in life sciences company creation and development including M&A.
- Brings expertise in chemical manufacturing including GMP and FDA regulatory compliance and submissions.
- Continues to build new companies, products, drugs, and diagnostics in oncology and infectious diseases
Boston, July 16, 2021 – The Communications Strategy Group Inc. (CSG), a life sciences consultancy, today announced that Richard Gabriel, a senior life sciences, chemical industry and M&A entrepreneur has joined the firm’s Advisory Board, and that Deirdre Y. Gillespie, M.D., has stepped down after serving for 15 years.
About Richard Gabriel, B.S., M.B.A.
Richard Gabriel began his career in large specialty chemical manufacturing at Ashland Chemical, W.R. Grace and Ventron, a division of Thiokol Corporation. In the mid-1980’s he built his first GMP, FDA-registered drug manufacturing plant, which become Pharm-Eco Laboratories, Inc., a California company which he moved to Lexington, Massachusetts. As the company grew with several locations, he moved the main operation to Harvard, Massachusetts, the first tenant at the former U.S. Army’s Fort Devens site, where he was the first biopharmaceutical company to build a 165,000 sq. ft. GMP manufacturing facility. In 2000, Pharm-Eco was sold to Johnson Matthey and remains in operation today in North Andover and Harvard.
Mr. Gabriel then moved to DNAPrint Genomics, a publicly traded company specializing in forensics, human and animal ancestry, one of the first to use DNA testing to provide investigators with a rough portrait of a ‘person of interest’. DNAPrint Genomics technology enabled law enforcement to apprehend over 10 serial killers and solve hundreds of cases using partial human remains.
Mr. Gabriel also served on the boards of WindGap Medical, Inc. and Predictive Oncology Inc. (POAI: NASDAQ). He recently resigned from the Predictive Oncology Board to take on the task of new technologies development as Senior Vice President of Research and Development for Predictive Oncology and all of its subsidiaries. He is also the site leader of TumorGenesis Inc. one of five of Predictive Oncology’s wholly owned subsidiaries. TumorGenesis focuses on developing new cancer cell lines and builds discovery tools that reflect the patient’s actual tumors, improving patient outcomes and helping researchers find new targets for cancer treatment. He is also Founder, CEO and President of GLG Pharma Corporation, a STAT3 inhibitor and patient diagnostics company focused on oncology.
“We are especially fortunate to have Mr. Gabriel, a highly talented and experienced professional, advising our team,” said Ted Agne, CSG president. “We’ve known and worked with him for many years and have always appreciated his tremendous knowledge of company creation and manufacturing. We are also very grateful for Dr. Gillespie’s advice and support over these many years and wish her continued success.”
About The Communications Strategy Group Inc.
Founded in 1987, CSG is a US-based international consultancy providing corporate/financial relations, business development, M&A and crisis management services to the life sciences, biotechnology, medical device and advanced technology sectors. The firm specializes in working with UK and European companies seeking to boost their global recognition. CSG is partnered with Cabinet Privé de Conseils SA, Geneva, and Zyme Communications, Ltd., Cambridge, UK.
###
Contacts:
Edward D. Agne
The Communications Strategy Group Inc.
+1781 888 0099
edagne@comstratgroup.com
Frank Pietrucha
The Communications Strategy Group Inc.
+1202-253-7376
fpietrucha@comstratgroup.com